Skip to main content
. Author manuscript; available in PMC: 2024 Feb 15.
Published in final edited form as: Am J Cardiol. 2022 Nov 22;189:121–130. doi: 10.1016/j.amjcard.2022.10.041

Figure 1.

Figure 1.

Trends in annual prescription rates for SGLT2 inhibitors and GLP-1 receptor agonists in integrated health system clinics, showing (A) an increase in prescription rates for SGLT2is and no significant change in prescription rates for GLP1-RAs in the overall cohort, and (B) a significant increase in SGLT2i prescription rates and a slight increase in GLP1-RA prescription rates in the high-risk patient cohort. Rates remain low overall in both cohorts.